TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04157478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Radiation therapy will be delivered in daily fractions of 2 Gy given 5 days a week for a total of 60 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be delivered in daily fractions of 2 Gy given 5 days a week for a total of 60 Gy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 150-200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 150-200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
Study: NCT01055028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg, IV every 21 days x 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg, IV every 21 days x 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Regimen A / Treatment 1: 200 mg/m² IV over 3 hours every 21 days.~Regimen B / Treatment 2: 90 mg/m² weekly x 3 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Regimen A / Treatment 1: 200 mg/m² IV over 3 hours every 21 days.~Regimen B / Treatment 2: 90 mg/m² weekly x 3 of a 28-day cycle
Study: NCT05406973

Intervention type: DEVICE
Group type: OTHER
Intervention: SBK microkeratome versus femtosecond laser in flap creation
Description: prospective comparative non randomized interventional clinical study

Intervention type: DEVICE
Group type: OTHER
Intervention: SBK microkeratome versus femtosecond laser in flap creation
Description: prospective comparative non randomized interventional clinical study
Study: NCT00529295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: Titrated oral misoprostol: one tablet of 200 microgram was dissolved in water 200 ml, and 20 ml P.O. per one hour for 4 doses, then titrated against uterine response; Vaginal misoprostol: 25 microgram per vagina

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: Titrated oral misoprostol: one tablet of 200 microgram was dissolved in water 200 ml, and 20 ml P.O. per one hour for 4 doses, then titrated against uterine response; Vaginal misoprostol: 25 microgram per vagina
Study: NCT01798602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin or identical placebo
Description: Tablet crushed for administration via feeding tube

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo for rosuvastatin
Study: NCT02071615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg tablet given once by mouth
Description: 3-arm, single-drug dosage comparison study
Study: NCT02930343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic diseases

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic diseases

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: 5-aminosalicylic acid (5-ASA) is the active component of sulfasalazine; the specific mechanism of action of 5-ASA is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF)
Study: NCT04473638

Intervention type: PROCEDURE
Intervention: Arthroscopic Deltoid Repair
Description: . A 4.5 mm arthroscopic set was used to clean the joint and assess medial and associated injuries. After deltoid injury confirmation through the method already mentioned, the medial gutter was prepared. The ideal positioning for the bone anchor in the medial malleolus followed Vega's recommendations and was located in the inferolateral quadrant created by the intersection of two lines: (1) tibia-talar joint line and (2) tangent line to the medial malleolus joint surface.(14). Sutures were passed respecting the safe zone illustrated by Acevedo at al, at the area between the posterior tibial tendon and the saphenous vein (16-25mm) (15). Sutures were passed but not tightened.
Study: NCT00449813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: 40 mg Pantoprazole
Study: NCT01087684

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Argon laser trabeculoplasty
Description: Argon laser 600-800 mW, 0.1seconds, 50 micron spot size, 45 - 55 burns over 180 degrees of trabecular meshwork

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser trabeculoplasty
Description: Selective laser trabeculoplasty 0.7 - 0.8 mJ, 400 micron spot size, 3 nanosecond, 45 - 55 burns over 180 degrees of trabecular meshwork.
Study: NCT02414919

Intervention type: DRUG
Intervention: Mirena (Levonorgestrel IUS, BAY86-5028)
Description: Levonorgestrel-releasing intrauterine device 20 mcg/day

Intervention type: DRUG
Intervention: ParaGard
Description: Copper T380A

Intervention type: DRUG
Intervention: Implanon/Nexplanon
Description: Etonorgestrel contraceptive implant
Study: NCT04750382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008+Cisplatin+Gemcitabine
Description: Participants will receive HX008 3mg/kg, Day 1,Q3W for up to 2 years + Cisplatin 75mg/m\^2, Day 1, Q3W for up to 6 cycles +Gemcitabine 1250mg/m\^2, Day 1, Day 8, Q3W for up to 6 cycles
Study: NCT02423993

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QoL assessment
Description: For Quality of Life (QoL) assessment will be used the following validated questionnaires (in Russian):~1. The Medical Outcomes Study 36-Item Short Form Health Survey - SF-36.~2. The Audit of the Diabetes-Dependent Quality of Life - ADDQoL (С. Bradley et al, 1999, adjusted by Starostina E.G., 2003).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QoL assessment
Description: For Quality of Life (QoL) assessment will be used the following validated questionnaires (in Russian):~1. The Medical Outcomes Study 36-Item Short Form Health Survey - SF-36.~2. The Audit of the Diabetes-Dependent Quality of Life - ADDQoL (С. Bradley et al, 1999, adjusted by Starostina E.G., 2003).
Study: NCT02389192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZMAPP
Description: ZMappTM, a combination of three mouse/human chimeric monoclonal antibodies (mAbs; c4G6, c2G4, and c13C6-FR1) directed against Ebola virus glycoprotein epitopes
Study: NCT02657629

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Feeding Regimen
Description: Nocturnal continuous enteral feedings given from 8pm-8am with intermittent bolus feedings every 3 hours between 11am and 5pm. Continuous feedings given via gavage (nasogastric tube, orogastric tube or gastrostomy tube) and intermittent bolus feeds via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Bolus Feeding Regimen
Description: Intermittent bolus enteral feedings given after 3 hours for entire 24 hours period. Feedings given via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
Study: NCT06126536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crestal Maxillary Sinus Floor Elevation using Osseodensification
Description: Patients will be prepared for surgery with local anesthesia and thorough oral cavity disinfection. A full thickness crestal incision will be made slightly towards the palate to enhance the possibility of achieving primary wound closure. A conservative flap will be raised, extending slightly beyond the alveolar crest, to minimize flap-related issues. After preparing the osteotomy site using Densah burs and elevating the sinus to the desired height, the implant will be inserted into the osteotomy site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral Maxillary Sinus Floor Elevation
Description: A crestal incision with an anterior vertical releasing incision exposes the sinus's lateral wall. A mucoperiosteal flap is carefully reflected, revealing the sinus. A bony window is created using a Piezoelectric device, and after elevation, the sinus floor is carefully lifted with various curettes. Implant osteotomies follow standard placement protocol, with precautions against sinus membrane perforation. Nanobone is used as graft material, mixed with saline and gently packed into the sinus. A resorbable membrane is placed on the window's outer surface, secured with circumferential resorbable sutures, and the flap is sutured for closure.
Study: NCT00516503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baclofen/amitriptyline/ketamine gel
Description: Applied topically

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Applied topically
Study: NCT02909751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin 90 mg/m2 iv
Description: Max. 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/m2 iv
Description: Max. 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide 600 mg/m2 iv
Description: Max. 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 600 mg/m2 iv
Description: Max. 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv
Description: Max. 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv
Description: Max. 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)
Description: Max. 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)
Description: Max. 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)
Description: Max. 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)
Description: Max. 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol 300 mg x 3 daily
Description: Max. 6 months
Study: NCT02260739

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Study: NCT04919759

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: R-Basic
Description: Participants in the R-Basic arm received access to a static website that contained educational materials on healthier eating and physical activity and the study questionnaires. The R-Basic intervention was implemented in the University of Sharjah.
Study: NCT02260739

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Study: NCT02321748

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast

Intervention type: DRUG
Group type: OTHER
Intervention: Montelukast

Intervention type: DRUG
Group type: OTHER
Intervention: ASP2151

Intervention type: DRUG
Group type: OTHER
Intervention: ASP2151
Study: NCT04312776

Intervention type: OTHER
Intervention: none intervention

Intervention type: OTHER
Intervention: none intervention
Study: NCT02678624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment according to the Collabri model
Description: The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
Study: NCT03669562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil Liposome for Injection
Description: intravenous infusion Alprostadil Liposome

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion liposome control
Study: NCT04127058

Intervention type: DRUG
Group type: OTHER
Intervention: Iloperidone
Description: Oral Tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Iloperidone
Description: Oral Tablet
Study: NCT00377455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: 62.5 mg by mouth (PO) twice daily (Bid) for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
Study: NCT02509780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vichy
Description: Volunteers will be asked during 3 days to take their usual intake of fluids. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 1 pm. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 7 am and 7 pm. Ph and density measurement of urine will be made three times a day, at 7 am, 2 pm and 8 pm.
Study: NCT02794064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tri-modal imaging
Description: This tri-modal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified
Study: NCT02962674

Intervention type: DEVICE
Group type: OTHER
Intervention: prostaFix System
Study: NCT00771667

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (IP)
Description: Induction phase (Week 0-8) (IP) - Placebo IV group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 1mg/kg (IP)
Description: Induction phase (Week 0-8) (IP) - Ustekinumab 1 mg/kg IV group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 3 mg/kg (IP)
Description: Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 6 mg/kg (IP)
Description: Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV - Responder - Placebo SC (MP)
Description: Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)
Description: Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab IV - Responder - Placebo SC (MP)
Description: Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)
Description: Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab IV - Nonresponder - Placebo SC (MP)
Description: Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Placebo SC at Week 8 and Week 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
Description: Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
Study: NCT03391908

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac imaging tests
Description: Patients will undergo non-invasive Cardiac Computed Tomography for assessment of coronary plaques and myocardial perfusion, and invasive intracoronary imaging tests (coronary angiography, Intravascular ultrasound, optical coherence tomography and FFR). If imaging will reveal existence of a significant coronary plaque, a percutaneous coronary intervention (PCI - stenting) will be performed.
Study: NCT02071615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil 200mg tablet given once by mouth
Description: 3-arm, single-drug dosage comparison study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffein 200mg tablet given once by mouth
Description: 3-arm, single-drug dosage comparison study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT02289625

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: six month of Exercise training will be conducted in individuals with moderate to severe sleep apnea. The training include aerobic exercise, resistance exercise, flexibility.
Study: NCT04919759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R-Enhanced
Description: The R-Enhanced intervention was guided by the Social Cognitive Theory and employed a variety of behavior modification strategies, including self-monitoring, goal setting, self-efficacy, and social support to facilitate changes in diet and physical activity. In addition, participants in the R-Enhanced intervention had online access to a nutritionist. The R-Enhanced intervention was implemented in the United Arab Emirates University.
Study: NCT02858726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845 0.5 mcg/kg
Description: IV medication delivered three times/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845 1 mcg/kg
Description: IV medication delivered three times/week
Study: NCT04371926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate
Description: Patients will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.~Staff will receive HCQ sulfate 400mg/week for 4 weeks
Study: NCT03202849

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D and A
Description: A single dose of Vitamin A and Vitamin D will be given.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D and Placebo
Description: A single dose of Vitamin D plus a placebo will be given.
Study: NCT00423007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02488317

Intervention type: OTHER
Group type: OTHER
Intervention: Decision Aid
Description: Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
Study: NCT02951117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-838
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-838
Description: Intravenous infusion
Study: NCT01368341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenoxymethylpenicillin
Description: Tablet 650 mg, 2 tablets, t.i.d., 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Capsula, 500 mg, t.i.d., 14 days